Sigrid Therapeutics is developing SiPore21®, an orally ingested medical device designed to lower blood sugar levels in prediabetics and newly diagnosed type 2 diabetics. This gel-based solution aims to prevent the progression to type 2 diabetes, addressing the rising global prevalence of lifestyle diseases linked to poor diet and inactivity.
Funding
Funding not disclosed
Founders
Product
Problem
Globally, a significant portion of deaths are attributed to lifestyle diseases like obesity, type 2 diabetes, and heart disease, often stemming from poor diet and physical inactivity. Prediabetes, a condition of elevated blood sugar, often progresses to type 2 diabetes if left unmanaged. Currently, there are limited treatment options specifically designed for individuals with prediabetes.
Solution
Sigrid Therapeutics is developing SiPore21®, an orally ingested medical device formulated as a consumer-friendly gel, designed to reduce blood sugar levels in individuals with prediabetes and newly diagnosed type 2 diabetes. SiPore21® is designed to be easily consumed. By lowering blood sugar, SiPore21® aims to prevent or delay the progression from prediabetes to type 2 diabetes. The product candidate originates from research conducted at Stockholm University and the Karolinska Institute.
Target Audience
The primary target audience includes individuals with prediabetes and those newly diagnosed with type 2 diabetes.
Features
- Orally ingested gel formulation for ease of use.
- Designed to lower blood sugar levels in prediabetics and newly diagnosed type 2 diabetics.
- Aims to prevent the progression of prediabetes to type 2 diabetes.